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Abstract
Background: Hypertension, diabetes and obesity are not isolated findings, but a series of interacting interactive
physiologic derangements. Taking into account genetic background and lifestyle behavior, AI (autonomic imbalance)
could be a common root for RHTN (resistant hypertension) or RHTN plus type 2 diabetes (T2D) comorbidity
development. Moreover, circadian disruption can lead to metabolic and vasomotor impairments such as obesity, insulin
resistance and resistant hypertension. In order to better understand the triggered emergence of obesity and T2D
comorbidity in resistant hypertension, we investigated the pattern of autonomic activity in the circadian rhythm in
RHTN with and without type 2 diabetes (T2D), and its relationship with serum adiponectin concentration.
Methods: Twenty five RHTN patients (15 non-T2D and 10 T2D, 15 males, 10 females; age range 34 to 70 years)
were evaluated using the following parameters: BMI (body mass index), biochemical analysis, serum
adiponectinemia, echocardiogram and ambulatory electrocardiograph heart rate variability (HRV) in time and
frequency domains stratified into three periods: 24 hour, day time and night time.
Results: Both groups demonstrated similar characteristics despite of the laboratory analysis concerning T2D like fasting
glucose, HbA1c levels and hypertriglyceridemia. Both groups also revealed disruption of the circadian rhythm: inverted
sympathetic and parasympathetic tones during day (parasympathetic > sympathetic tone) and night periods
(sympathetic > parasympathetic tone). T2D group had increased BMI and serum triglyceride levels (mean 33.7 ± 4.0 vs
26.6 ± 3.7 kg/m
2 - p = 0.00; 254.8 ± 226.4 vs 108.6 ± 48.7 mg/dL - p = 0.04), lower levels of adiponectin (6729.7 ± 3381.5
vs 10911.5 ± 5554.0 ng/mL - p = 0.04) and greater autonomic imbalance evaluated by HRV parameters in time domain
compared to non-T2D RHTN patients. Total patients had HRV correlated positively with serum adiponectin (r = 0.37
[95% CI -0.04 - 1.00] p = 0.03), negatively with HbA1c levels (r = -0.58 [95% CI -1.00 - -0.3] p = 0.00) and also adiponectin
correlated negatively with HbA1c levels (r = -0.40 [95% CI -1.00 - -0.07] p = 0.02).
Conclusion: Type 2 diabetes comorbidity is associated with greater autonomic imbalance, lower adiponectin levels
and greater BMI in RHTN patients. Similar circadian disruption was also found in both groups indicating the
importance of lifestyle behavior in the genesis of RHTN.
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Hypertension, diabetes and obesity are not isolated find-
ings, but a series of interactive physiologic derangements
[1]. For instance, it is well known that obesity and dia-
betes mellitus are factors associated with resistance to
antihypertensive drugs. An understanding of interactions
among these pathophysiologic pathways can assist in
choosing treatment and thereby improving total cardio-
vascular risk management [1].
Autonomic imbalance, characterized by a hyperactive
sympathetic system and a hypoactive parasympathetic
system, is associated with various pathological condi-
tions [2,3]. Over time, excessive energy demands on the
system can lead to premature aging and diseases [2,3].
Therefore, autonomic imbalance may be a final common
pathway to increased morbidity and mortality from a
host of conditions and diseases, including cardiovascular
disease [4,5].
Heart rate variability (HRV) may be used to assess
autonomic imbalances, diseases and mortality [6]. Mea-
sures of heart rate variability (HRV) in both time and
frequency domains have been used successfully to index
vagal activity [7]. Nevertheless, while there are some dif-
ferences among HRV parameters found in many studies,
the consensus is that lower values of these indices of
vagal function are associated prospectively with death
and disability [8]. Parasympathetic activity and HRV
have been associated to immune dysfunction and
inflammation, which have been implicated in a wide
range of conditions including CVD and diabetes [2,3].
There is a pathogenic link between autonomic imbal-
ance and insulin resistance and hypertension onset
[9-14]. In addition to genetic background and environ-
ment, AI (autonomic imbalance) could be a common
root of HTN (hypertension) or HTN plus T2D (type 2
diabetes) comorbidity development. T2D comorbidity
can be added to HTN by decreased energy dissipation,
gaining weight and then insulin resistance [15]. It is
known that a chronic increase in sympathetic outflow
has been reported to decrease b-adrenergic responsive-
ness itself, by a down-regulation of b-adrenergic recep-
tors, which are known to mediate energy expenditure
either at rest or after food intake [16].
These obesity-related disorders including metabolic
syndrome, diabetes, atherosclerosis, hypertension, and
coronary artery disease are associated with dysregulated
adipokine(s) expression such as adiponectin [17].
Adiponectin is a hormone that is produced by adipo-
cytes [18]. In patients with type 2 diabetes mellitus, low
plasma adiponectin levels are associated with insulin
resistance and have also been shown to be an indepen-
dent predictor of type 2 diabetes mellitus [19]. In addi-
tion, sympathetic nervous overactivity is associated with
hypoadiponectinemia [20,21]. However, there is still
limited information on the relationship between plasma
adiponectin, obesity, T2D and cardiac autonomic nervous
function, especially in resistant hypertension (RHTN).
In order to better understand the triggered emergence
of obesity and T2D comorbidity in resistant hyperten-
sion, we investigated the pattern of autonomic activity
in the circadian rhythm in this population with and
without type 2 diabetes (T2D) and its relationship with
serum adiponectin concentration.
Methods
Twenty-five (25) RHTN subjects [22] [15 non-T2D and
10 T2D, 15 (60%) females and 10 (40%) males], regularly
f o l l o w e di nt h ea m b u l a t o r ys ervice of cardiovascular
clinical pharmacology, complying with pharmacological
prescription for HTN and T2D, were recruited to parti-
cipate in this transversal study. The diagnosis of resis-
tant hypertension required a good office blood pressure
measurement technique and ambulatory blood pressure
monitoring (ABPM) to confirm persistently elevated
blood pressure levels [23]. Pseudoresistance cases,
including lack of blood pressure control secondary to
poor medication adherence, were properly observed and
excluded [24]. White coat hypertension (WCH) was
excluded by ABPM [23]. Regarding obstructive sleep
apnea (OSA), only patients classified as “low risk” by
Berlin sleep questionnaire were enrolled [25]. Resistant
hypertension include patients whose blood pressure is
uncontrolled with use of more than three medications
or patients whose blood pressure is controlled, but
required four or more medications to achieve blood
pressure goals [23]. All subjects provided written
informed consent and the study was approved by the
local ethics committee.
The exclusion criteria comprised: acute or moderate-
severe renal dysfunction, non-complied pharmacologi-
cal prescription, use of beta-blockers within the last six
months, severe obesity (body mass index ≥ 35 kg/m
2),
heart failure (ejection fraction < 50%), valvular heart
disease, cardiomyopathies, primary hyperaldosteronism
[aldosterone:PRA ratio > 20 ng per 100 mL per ng.ml
(-1)h(-1)], sleep apnea (classified as “high risk” by the
Berlin sleep questionnaire), atrial fibrillation, sick sinus
syndrome, supraventricular and ventricular tachycar-
dias, aortic disease (Marfan’s syndrome, coarctation of
the aorta, aneurysms or aortic surgery, etc), history of
coronary artery disease or proven coronary artery dis-
ease by coronary angiography or noninvasive tests,
familial hyperlipidemia, asthma or chronic obstructive
lung disease, pregnancy or oral contraceptive use,
connective tissue disorders, neurological problems,
malignancies, psychiatric diseases, other than T2D
endocrinological diseases,s m o k i n g ,a l c o h o lu s ea n d
drug abuse.
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Blood pressure was assessed by considering the orienta-
tions of the last guideline on hypertension of the Eur-
opean Society of Cardiology [26]. Blood pressure (SBP -
systolic blood pressure/DBP - diastolic blood pressure)
was measured three times for each subject using a digi-
tal sphygmomanometer (Omron HEM-711DLX) on the
right upper arm in the sitting position after a 10-minute
rest. The average of two consecutive measurements was
used with a variation lower than 5 mmHg.
Laboratory analysis
All subjects underwent the following laboratory tests:
hemogram, serum fasting glucose, glycolized hemoglobin
(HbA1c), serum urea and creatinine, serum total choles-
terol, serum LDL-cholesterol fraction, serum HDL-choles-
terol fraction, serum triglycerides, serum uric acid, serum
sodium and potassium, and plasma adiponectin levels
(Quantikine
® Human total adiponectin/Acrp30 Immu-
noassay DRP 300, R&D Systems, Inc., Minneapolis, USA).
Echocardiographic examination
All subjects were submitted to standard transthoracic
echocardiography in the left lateral decubitus position
by using a Vivid 7 Pro machine with a 2.5 Mhz probe
(General Electric, Florida, USA). Standard transthoracic
views were used to determine end-diastolic and end-sys-
tolic volumes, stroke volume index, left ventricular ejec-
tion fraction (LVEF), transmitral E and A waves
velocities, E/A ratio, tissue doppler velocity of the mitral
annulus and left ventricular mass index (LVMI). The
left ventricular diastolic dysfunction (LVDD) was
assessed by the Omnen SR and Nishimura RA algo-
rithm[27]. The echocardiographic examination was per-
formed by only one experienced cardiologist examiner.
There was no intra or inter-observer measurement
variability.
Heart rate variability
Heart rate variability (HRV) parameters were derived
from the recording of 24-hour Holter monitoring and
analyzed in time and frequency domains. Measures were
stratified into three time periods for time domain:
24 hour period (24 h), day time period (DT), 1 p.m. to
5p . m .a n dn i g h tt i m ep e r i o d( N T ) ,f r o m2a . mt o6a . m .
Frequency domain measures were stratified into two per-
iods of one hour each at 3 a.m. (night time period - NT)
and 3 p.m. (day time period - DT). A three-channel, 24-
hour Holter recording was obtained from each subject
using the Cardio light digital 24-hour recorder device
and the CardioSmart Institutional CS 550 software
(Cardio Sistema Comércio e Indústria Ltda, São Paulo,
SP, Brazil).
Time domain HRV parameters included the following
measures [6,28]:
- rMSSD (ms): Square root of the mean of the
squares of differences between successive RR
intervals.
- SDNN (ms): Standard deviation of all normal RR
intervals in 24-hour Holter recording.
- SDANN (ms): Standard deviation of RR intervals
means in all 5-minute segments of 24-hour
recording.
- pNN50 (%): Percentage of differences between suc-
cessive RR intervals that are greater than 50 ms.
Frequency domain measures were calculated using the
Fast Fourier Transform (FFT) to break down the time
series to its underlying periodic function. Frequency
domain HRV parameters included the following mea-
sures [6,28]:
- Low frequency (LF) and high frequency (HF) mea-
sured in normalized units, which represent the rela-
tive value of each power component in proportion
to the total power minus the very low frequency
(VLF) component. Normalized LF (LF nu) was cal-
culated as LF power in normalized units LF/(total
power-VLF) × 100, and normalized HF (HF nu) as
HF power in normalized units HF/(total power-VLF)
× 100. Low frequency (LF) and high frequency (HF).
LF nu and HF nu denote the energy in the heart
period power spectrum between 0.04 and 0.15 Hz
(which is due to the joint action of the vagal and
sympathetic components on the heart, with a predo-
minance of the sympathetic ones) and 0.15 and 0.40
Hz (which corresponds to the respiratory modula-
tion and is an indicator of the performance of the
vagus nerve on the heart), respectively. “Day time”
and “night time” were established at 3:00 p.m. and
3:00 a.m., respectively, in order to collect HRV data
during wake and sleep periods.
Statistical analysis
Data were expressed as mean (μ) and standard deviation
(SD) or mean (μ) and standard error of the mean (SEM)
for HRV measures. Unpaired groups were compared
using Mann-Whitney U test while correlation analysis
were performed using Spearman’s rank test. Fisher’s
exact test was used to determine whether a certain
group had significantly different proportion of a particu-
lar characteristic. The level of statistical significance
accepted was less than 0.05. All data were entered into
a spreadsheet program (MS Excel Microsoft Corp,
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statistics were performed by Analyse-it version 2.21
Excel 12+ (Analyse-it Software Ltd., Leeds, UK), a statis-
tical add-in program for Excel (MS Excel Microsoft
Corp, Phoenix, Arizona, USA).
Results
The general characteristics of the study groups are listed
in table 1. No statistical differences were observed between
the non-T2D and T2D subgroups with respect to age and
gender. The mean ages were 54.7 and 54.9 in non-T2D
and T2D patients, respectively. Women made up equally
40% of the patients in these groups. Both groups demon-
strated similar characteristics despite of the laboratory
analysis concerning T2D diagnosis like fasting glucose
(167.8 ± 9.2 vs 92.9 ± 9.2 mg/dL - p < 0.0001) and HbA1c
levels (9.3 ± 2.1 vs 5.8 ± 0.3% - p < 0.0001) (Table 1).
However, the T2D group showed a greater BMI and
higher serum triglyceride levels than the non-T2D group
(33.7 ± 4.0 vs 26.6 ± 3.7 kg/m
2,-p=0 . 0 0 0 2 ;2 5 4 . 8±2 2 6 . 4
vs 108.6 ± 48.7 mg/dL - p = 0.041) (Table 1). Concerning
HRV parameters, the following evaluations were reduced
in T2D: 24 hour-SDNN (89.1 ± 19.9 vs 122.9 ± 39.5 ms;
p = 0.0009), Day time SDNN (58.2 ± 13.6 vs 78.5 ± 24.9
ms; p = 0.03), 24 hour-SDANN (79.8 ± 17.1 vs 122.9 ±
39.5 ms; p = 0.0012), Day time SDANN (47.8 ± 3.5 vs 65.5
± 6.5 ms; p = 0.03), Day time rMSSD (13.8 ± 1.9 vs 19.8 ±
2.2; p = 0.05), 24 hour-pNN50 (1.8 ± 2.1 vs 5.3 ± 6.4%;
p = 0.047), Day time pNN50 (0.5 ± 0.5 vs 2.6 ± 2.9%; p =
0.035) and Night time pNN50 (4.2 ± 1.6 vs 12.4 ± 4.7; p =
0.04) (Figure 1). Although the remaining HRV parameters
in time domain have demonstrated greater autonomic
imbalance in the T2D group, they did not achieve statisti-
cally significance (p > 0.05) (Figure 1).
Frequency domain parameters demonstrated inverted
pattern of tone intensity for both branches of the auto-
nomic system during day and night periods in both
groups. Regarding the non-T2D group, LF nu during
day and night were 22.5 ± 3.2 vs 51.0 ± 7.1 (p = 0.00)
and HF nu were 77.5 ± 3.2 vs 48.9 ± 7.1 (p = 0.00),
respectively. For the same group, HF nu during day and
night were 77.5 ± 3.2 vs 48.9 ± 7.1 (p = 0.00), respec-
tively. Regarding the T2D group, LF nu during day and
night were 25.7 ± 7.1 vs 47.1 ± 7.3 (p = 0.01) and HF
nu were 74.2 ± 7.1 vs 52.8 ± 7.3 (p = 0.01), respectively
(Figure 2). For the same group, HF nu during day and
night were 74.2 ± 7.1 vs 52.8 ± 7.3 (p = 0.01), respec-
tively (Figure 2). There were no differences between
non-T2D and T2D groups in frequency domain para-
meters (Table 2).
Total patients (non-T2D and T2D groups) had HRV cor-
related positively with serum adiponectin (r = 0.37 [95% CI
-0.04 - 1.00] p = 0.03) and negatively with HbA1c levels
(r = -0.58 [95% CI -1.00 - -0.3] p = 0.00). Total patients
had also adiponectin correlated negatively with HbA1c
levels (r = -0.40 [95% CI -1.00 - -0.07] p = 0.02) (Figure 3).
Table 1 General characteristics of study groups
Characteristic/Variable Non-T2D group (n = 15) T2D group (n = 10) p-value
Gender 60% (female)/40% (male) 60% (female)/40% (male) 1.00
Age (year) 54.7 ± 10.0 [49.2 - 60.3] 54.9 ± 8.7 [48.7 - 61.1] 0.89
Hemoglobin (g/dL) 13.6 ± 1.1 [13.0 - 14.3] 13.6 ± 1.4 [12.6 - 14.6] 0.97
Hematocrit (%) 41.1 ± 2.7 [39.6 - 42.7] 40.4 ± 4.0 [37.5 - 43.3] 0.56
Body mass index (kg/m
2)* 26.6 ± 3.7 [24.5 - 28.7] 33,7 ± 4,0 [30.8 - 36.6] 0.00
Fasting glucose (mg/dL)* 92.9 ± 9.2 [87.9 -98.0] 167.8 ± 64.0 [117.8 - 258.2] 0.00
HbA1c (%)* 5.8 ± 0.3 [5.6 - 6.0] 9.3 ± 2.1 [7.7 - 10.8] 0.00
Serum adiponectin (ng/mL)* 10911.5 ± 5554.0
[7835.7 - 13987.2]
6729.7 ± 3381.5
[4310.8 - 9148.7]
0.04
Serum urea (mg/dL) 34.2 ± 12.8 [27.1 - 41.3] 38.0 ± 7.8 [32.4 - 43.6] 0.46
Serum creatinine (mg/dL) 0.9 ± 0.2 [0.8 - 1.0] 0,9 ± 0.1 [0.7 - 1.0] 0.93
Total cholesterol (mg/dL) 193.7 ± 48.8 [166.7 - 220.8] 193.5 ± 33.2 [169.8 - 217.2] 0.36
LDL-cholesterol (mg/dL) 119.4 ± 47.0 [93.4 - 145.4] 104.3 ± 31.1 [82.0 - 126.6] 0.84
HDL-cholesterol (mg/dL) 50.8 ± 17.0 [41.4 - 60.2] 42.9 ± 11.0 [35.0 - 50.8] 0.21
Serum triglycerides (mg/dL)* 108.6 ± 48.7 [81.6 -135.6] 254.8 ± 226.4 [92.9 - 416.7] 0.04
Uric Acid (mg/dL) 5.3 ± 1.1 [4.7 - 6.0] 5.7 ± 1.2 [4.8 - 6.5] 0.60
Na (mEq/L) 140.1 ± 2.2 [138.9 - 141.3] 138.8 ± 2.0 [137.3 - 140.3] 0.17
K (mEq/L) 4.3 ± 0.5 [4.0 -4.6] 4.2 ± 0.4 [3.8 - 4.5] 0.49
UACR (mg/g) 11.3 ± 13.2 [4.0 - 18.7] 138.2 ± 229.8 [-26.2 - 302.6] 0.17
Office SBP (mmHg) 154.3 ± 21.6 [142.3 -166.2] 156.5 ± 30.6 [134.7 - 178.4] 0.93
Office DBP (mmHg) 92.9 ± 10.8 [86.9 - 98.8] 90.1 ± 18.2 [77.0 - 103.1] 0.33
The values are expressed as means ± standard deviation; [95% confidence interval]; (*) Statistical significance (p < 0.05); Non-T2D: non type 2 diabetes resistant
hypertension; T2D: type 2 diabetes resistant hypertension.
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Page 4 of 12Figure 1 Autonomic imbalance. Heart rate variability (HRV) in time domain between non type 2 diabetes (T2D) (white column) and T2D (black
column) RH patients. A: SDNN (ms): Standard deviation of all normal RR intervals in 24-hour Holter recording; B: SDANN (ms): Standard deviation
of RR means intervals in all 5-minute segments of 24-hour recording; C: rMSSD (ms): Square root of the mean of the squares of differences
between successive RR intervals; D: pNN50 (%): Percentage of differences between successive RR intervals that are greater than 50 ms; DT: Day
time (1 p.m. - 5 p.m.); NT: Night time (2 a.m. - 6 a.m.); 24 h: 24 hours; (*) Statistical significance (p < 0.05).
Figure 2 LF nu: Circadian disruption. Heart rate variability (HRV) in frequency domain between non type 2 diabetes (T2D) (white column) and
T2D (black column) RH patients. LF nu: Low frequency in normalized units; HF nu: High frequency in normalized units; DT: Day time (3 p.m.); NT:
Night time (3 a.m.); Statistical significance: (*) p < 0.05 vs LF nu DT non-T2D (**) p < 0.05 vs LF nu DT T2D; (§) p < 0.05 vs HF nu DT non-T2D; (†)
p < 0.05 vs HF nu DT T2D.
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ing more anti-hypertensive drugs than the non-T2D
group (Table 3). In addition, the T2D group demon-
strated greater prevalence of left ventricular diastolic
dysfunction than the non-T2D group despite of similar
left ventricle hypertrophy index (Table 4).
Discussion
Important findings
We found that the AI is more impaired in T2D RHTN
patients than the non-T2D group. As expected, the T2D
group had greater BMI and serum triglycerides than the
non-T2D group. Considering the total of patients, an
established negative correlation between HbA1c levels
and serum adiponectin concentration was also observed.
In addition to these well-known characteristics between
non-T2D and T2D patients, considering the total
patients, HRV correlated positively with adiponectin and
negatively with HbA1c levels. Interestingly, despite of
the higher AI in the T2D subgroup, both groups
demonstrated similar inverted pattern of sympathetic
and parasympathetic tones during day and night periods.
As far as we know, this is the first time that AI and
circadian disruption (CD) were evaluated in RHTN
patients with or without T2D in order to better under-
stand their synergistic role in obesity and T2D associa-
tion with RHTN.
Historical aspects of autonomic dysfunction
Since the fifth decade, cardiovascular autonomic research-
ers have cogitated whether AI would be a cause or conse-
quence of hypertension [29]. Subsequently, it was
demonstrated that AI could lead not only to hypertension,
but also to T2D [7]. Reasonable amount of data provide
evidences for prediction hypertension or diabetes onset
due autonomic imbalance evaluated by HRV parameters
in time or frequency domain [9-14]. Autonomic imbalance
causes, at first, increased insulin sensitivity and reduced
energy dissipation [15]. Concomitantly, insulin resistance
impairs the overall mean levels of cardiac autonomic mod-
ulation among persons with T2D [30].
Pathogenesis of autonomic dysfunction and metabolic
disorders
The increased concentration of angiotensin II inhibits
intracellular signaling to GLUT 4 expression on the sur-
face of the cells leading to insulin resistance [31,32].
However, the observation that not all subjects follow
this link suggests that other factors, including genetic
predisposition and environment, can influence it at var-
ious levels [33-38].
A chronic increase in sympathetic outflow has been
reported to decrease b-adrenergic responsiveness itself,
through down-regulation of b-adrenergic receptors,
which are known to mediate energy expenditure both at
Table 2 Heart rate variability (HRV) in time and frequency domain between non-T2D and T2D resistant hypertension
patients
HRV variable Non-T2D group (n = 15) T2D group (n = 10) p-value
24 hour-SDNN * 131.5 ± 9.9 [110 - 152,9] 89.1 ± 6.2 [74.9 - 103.3] 0.00
Day time SDNN * 78.5 ± 6.4 [64.7 - 92.3] 58.2 ± 4.3 [48.5 - 67.9] 0.03
Night time SDNN 104.7 ± 11.1 [80.8 -128.5] 84.7 ± 12.0 [57.6 - 111.8] 0.21
24 hour-SDANN * 122.9 ± 10.2 [101.0 - 144.8] 79.8 ± 5.4 [67.6 - 92.0] 0.00
Day time SDANN * 65.5 ± 6.5 [51.5 - 79.4] 47.8 ± 3.5 [39.7 - 55.9] 0.03
Night time SDANN 73.2 ± 10.7 [50.1 - 96.3] 67.3 ± 11.0 [42.3 - 92.3] 0.80
24 hour-pNN50 * 5.3 ± 1.6 [1.8 - 8.9] 1.8 ± 0.6 [0.3 - 3.3] 0.05
Day time pNN50 * 2.6 ± 0.7 [0.9 - 4.2] 0.5 ± 0.1 [0.1 - 0.8] 0.04
Night time pNN50 * 12.4 ± 4.7 [2.3 - 22.5] 4.2 ± 1.6 [0.5 - 7.9] 0.04
24 hour-rMSSD 27.4 ± 4.0 [18.7 - 36.1] 19.7 ± 3.6 [11.6 - 27.8] 0.17
Day time rMSSD * 19.8 ± 2.2 [14.9 - 24.7] 13.8 ± 1.9 [9.5 - 18.1] 0.05
Night time rMSSD 37.3 ± 8.2 [19.6 - 55.0] 27.8 ± 6.1 [14.0 - 41.6] 0.21
Day time LF nu 22.5 ± 3.2 [15.4 - 29.5] 25.7 ± 7.1 [9.6 - 41.8] 0.97
Night time LF nu 51.0 ± 7.1 [35.8 - 66.3] 47.1 ± 7.3 [30.5 - 63.8] 0.80
Day time HF nu 77.5 ± 3.2 [70.4 - 84.5] 74.2 ± 7.1 [58.1 - 90.3] 0.97
Night time HF nu 48.9 ± 7.1 [33.6 - 64.1] 52.8 ± 7.3 [36.2 - 69.4] 0.80
The values are expressed as means ± standard error of the mean; [95% confidence interval]; (*) Statistical significance (p < 0.05). SDNN (ms): Standard deviation
of all normal RR intervals in 24-hour Holter recording; SDANN (ms): Standard deviation of means of RR intervals in all 5-minute segments of 24-hour recording;
pNN50 (%): Percentage of differences between successive RR intervals that are greater than 50 ms; rMSSD (ms): Square root of the mean of the squares of
differences between successive RR intervals; LF nu: Low frequency in normalized units from the power spectra of HRV by computer analysis using Fast Fourier
Transformation (FFT); HF nu: High frequency in normalized units from the power spectra of HRV by computer analysis using FFT; Non-T2D: non type 2 diabetes
resistant hypertension; T2D: type 2 diabetes resistant hypertension.
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Page 6 of 12Figure 3 A: Correlation between HRV and glycosylated hemoglobin (HbA1c) levels of total RH patients (r = -58; [95% CI -1.0 - -0.3];
p = 0.00); B: Correlation between HRV and adiponectin of total RH patients (r = 0.37; [95% CI -0.04 - 1.0]; p = 0.03); C and D: Matrix
plot of the distribution of values between HRV and adiponectin; E and F: Matrix plot of the distribution of values between HRV and
HbA1c levels; G and H: Matrix plot of the distribution between HbA1c levels and adiponectin. Non-T2D group: white circles; T2D group:
black circles. Parameters for the matrix plot in means: Adiponectin (5548 ng/mL - Healthy volunteers evaluated with plasma EDTA of Quantikine
®
lab test), SDNN 24 h (141 ms)[6] and HbA1c (6.0%).
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Page 7 of 12rest and after food intake [16]. This mechanism could
result in a reduced ability to dissipate energy leading to
weight gain. At first glance, it appears to be in contrast
to the previous reports in rats, where the down-regula-
tion of b-adrenergic receptors, following chronic cate-
cholamine stimulation, has been associated with
increased insulin sensitivity [39]. Moreover, the hypotha-
lamus is a regulatory center of satiety and of the auto-
nomic nervous system (ANS). Therefore, abnormalities
in the hypothalamus may cause obesity and autonomic
dysfunction. This may explain the alterations observed
in the HRV indices [40].
Corroborating the mechanism above, the correlation
between high sympathetic activity and hypoadiponecti-
nemia was previously established [21]. Since we evalu-
ated RHTN patients and hypoadiponectinemia is also
associated with sympathetic activation and severity of
OSA [41], only true RHTN patients classified as “low
risk” (Berlin sleep questionnaire) of OSA diagnosis were
included in this study. We have found positive correla-
tion between HRV and adiponectinemia and it is prop-
erly presumable to us that this adipocytokine may play
an important role in the development of obesity and
T2D in RHTN by the AI patient status. Recently, an
interventional clinical trial with prolonged insulin-glu-
cose infusion was performed with healthy human sub-
jects in order to evaluate the effect of insulin on
adiponectin multimers and nuclear factor-kappaB (NF-
kB) activity in human endothelial cells [42]. Hyperinsuli-
nemic induction significantly decreased high molecular
weight and total adiponectin levels but increased NF-kB
activity in serum treated microvascular endothelial cells
[42].
Lifestyle and circadian disruption
Regarding the contribution of environment in the
genesis of resistant hypertension, obesity and T2D, the
circadian disruption seems to be an important compli-
cating factor. Disrupted circadian rhythms caused by
disturbed sleep-wake cycles, inactivity during the active
period, enhanced activity during the rest period and
high food consumption might lead to attenuated feeding
rhythms, disrupted metabolism and obesity [43]. This
lifestyle may cause high parasympathetic output to
the viscera leading to obesity, hyperinsulinemia, and
hyperlipidemia, or high sympathetic output to the mus-
cle and heart leading to vasoconstriction and hyperten-
sion [44]. In addition to the impairment of AI, circadian
disruption was found in both groups. Since the genetic
background allied to the disruption of the circadian
rhythm favors HTN and metabolic disorders, our results
are in accordance with the literature: findings in murine
models show the strong link between genetic back-
ground and circadian rhythm disruption in determining
the severity of metabolic disorders [43].
Hypoadiponectinemia and metabolic disorders
Diabetic patients had greater BMI and lower adiponectin
values compared to non-T2D patients. It was also nota-
ble that the diabetic group had greater BMI and higher
serum triglyceride levels than the non-diabetic group.
The association between BMI and hypertriglyceridemia
Table 3 Anti-hypertensive (anti-HTN) drugs distribution
Characteristic/Variable Non-T2D group (n = 15) T2D group (n = 10) p-value
Total anti-HTN drugs* 3.3 ± 0.5 [3.1 - 3.6] 4.1 ± 0.7 [3.6 - 4.6] 0.02
Thiazide diuretic 100% (15) 100% (10) -
Aldosterone receptor inhibitor 26.6% (4) 50% (5) 0.40
Angiotensin converting enzyme inhibitor 66.6% (10) 50% (5) 0.68
Angiotensin receptor blocker 40% (6) 70% (7) 0.23
Calcium channel blocker 86.6% (13) 100% (10) 0.50
Centrally acting anti-hypertensive drug 6.6% (1) 40% (4) 0.12
The values are expressed as means ± standard deviation; [95% confidence interval]; (*) Statistical significance (p < 0.05). Non-T2D: non type 2 diabetes resistant
hypertension; T2D: type 2 diabetes resistant hypertension.
Table 4 Echocardiographic parameters of study groups
Characteristic/Variable Non-T2D group (n = 15) T2D group (n = 10) p-value
LVEF (%) 70.3 ± 7.3 [66.3 -74.4] 66.5 ± 21.7 [51.0 - 82.0] 0.28
LVMI (g/m
2) 134.1 ± 30.9 [116.9 - 151.2] 148.4 ± 31.6 [125.8 - 171.0] 0.31
LVDD Present in 60% Present in 100% 0.05
The values are expressed as means ± standard deviation; [95% confidence interval]; Non-T2D: non type 2 diabetes resistant hypertension; T2D: type 2 diabetes
resistant hypertension; LVEF: left ventricle ejection fraction; LVMI: left ventricle mass index; LVDD: left ventricle diastolic dysfunction (assessed by the Omnen SR
and Nishimura RA algorithm [27]).
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tion, hypoadiponectinemia per se may not be the main
issue in metabolic alterations associated with obesity. A
harmonized pattern of rhythmic expression of adiponec-
tin by visceral and subcutaneous abdominal adipose
tissue seems to be crucial to body fat distribution home-
ostasis as well as to prevent metabolic alterations asso-
ciated with obesity [46].
Based on the above considerations, the imbalance of
autonomic function represents a primary defect leading to
RHTN and insulin resistance. Moreover, circadian disrup-
tion caused by behavior and genetic background disturbs
the balance between sympathetic and parasympathetic
branches during day and night periods. In our opinion, a
higher degree of AI underlies obesity and T2D onset in
RHTN compared to non-T2D RHTN (Figure 4).
Severity of hypertension and autonomic imbalance
However, the significant worsing in AI found in the
T2D group is of interest because we considered the null
hypothesis of no difference between groups due the
severity of hypertension such in RHTN. At first, we pre-
sumed that AI could be different in mild to moderate
stages of hypertension whilst in RHTN this difference
would be strongly attenuated. Since the degree of
impairment in cardiac autonomic control is proportional
to the severity of hypertension, and not necessarily
impaired in mild long-lasting essential hypertension
[47], T2D comorbidity would be determinant of AI in
mild to moderate hypertension, but not so decisive for
A Ii nR H T N .I nf a c t ,M u s s a l oHe ta l[ 4 7 ]c o m p a r e d
HRV between severe and mild hypertension. However,
the severe group was not stratified into non-T2D and
T2D subgroups. Once more, in accordance with the
clinical trials of our laboratory [48], RHTN proved to
have a plural complexity. The AI gap between both
groups demonstrated that RHTN per se is not an end
stage of hypertension disease. Especially in RHTN with-
out T2D, there is still a favorable residual autonomic
function which needs to be preserved or enhanced.
Pharmacologic perspectives for RHTN and T2D treatment
It is important to point out that in cases of T2D comor-
bidity, a better awareness of specific characteristics of
diabetes such as decreased energy expenditure, lipolysis
and insulin sensitivity can guide doctors to avoid drugs
which can enhance these phenomena such as conven-
tional or non-vasodilating beta-blockers [49]. However,
considerable heterogeneity exists within the b-blocker
class. Perhaps most important is a variation in adrener-
gic receptor selectivity; nevertheless, there is also varia-
bility in lipophilicity, intrinsic sympathomimetic activity
(ISA), membrane-stabilizing action, and vasodilating
properties [50]. Carvedilol, for instance, is a highly non-
selective lipophilic b-blocker with a1-blocking activity
and no ISA [51]. Its pharmacologic properties may be
associated with a more comprehensive treatment of AI
s i n c et h e yc a ni m p r o v ei n s u l i ns e n s i t i v i t yi nT 2 D
patients [52-54]. This mechanism, although very intri-
guing, needs further support from more complete
(possibly longitudinal) studies and opens a new and sti-
mulating field towards pharmacology intervention focus-
ing the improvement of autonomic imbalance in T2D
patients in order to optimize glucose metabolism in
addition to BP control in RHTN patients.
Non-pharmacologic treatment of RHTN in real-life
settings
There are different methods to measure the circadian
rhythm: sleep diaries, polysomnographic recording,
actimetry, chronotype identification, body temperature,
pre-sleep measures of melatonin secretion, cortisol
Figure 4 Circadian disruption and autonomic imbalance and their relationship with vasomotor and visceral disturbances in non-T2D
and T2D resistant hypertensive patients. The circadian disruption maximizes the autonomic imbalance in the development of obesity and
T2D in RH.
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approach of circadian rhythm may not need all these
methods, but simple oriented questions regarding day-
night behavior. In addition to the well-known lifestyle
factors to be assessed by anamnesis such as obesity, diet-
ary salt intake and alcohol consumption [22], we endorse
that the approach of the chronotype of RHTN patients
should also be encouraged by all hypertension guidelines.
The circadian disruption found in this study also rein-
forces the need for lifestyle change in RHTN. Even in
asymptomatic obese adults, abnormalities in circadian
blood pressure variability and endothelial function
exhibited unfavorable cardiometabolic profiles such as
elevated high-sensitivity C-reactive protein, fibrinogen,
fasting serum glucose and cardiac risk ratios (Total
Cholesterol:HDL-cholesterol and LDL-cholesterol:HDL-
cholesterol ratios) [56]. A more comprehensive ana-
mnesis over feeding behavior, physical inactivity during
the day, hyperactivity during the night (or repose) and
duration of sleepiness may help physicians and patients
think about strategies to avoid the circadian disruption.
Limitations of the study
Our main limitation was the recruitment of “true”
RHTN patients and then the small sample size is note-
worthy. Despite of the small sample size, it was possible
to identify greater AI in the T2D subgroup. We
assumed that the small sample size of the T2D group is
a result of the prevalent exclusion criteria of moderate
to severe renal dysfunction, history of coronary artery
disease and b-blocker already in use in this population.
General findings and future perspectives
We concluded that, in spite of circadian disruption, even
in RHTN patients there is a residual autonomic function
compared to T2D patients. Furthermore, it is clear that
the evaluation of BMI, adiponectin and HRV of RHTN
patients can reveal the risk of T2D association or future
development in this high risk population. However, an
appropriate risk matrix to evaluate this prognostic infor-
mation will demand a longitudinal clinical study with
significant greater sample size of RHTN patients.
Conclusion
Type 2 diabetes comorbidity is associated with greater
autonomic imbalance, lower adiponectin levels and
greater BMI in RHTN patients. Moreover, similar circa-
dian disruption was also found in both groups indicating
the importance of lifestyle behavior in the genesis of
RHTN. A better comprehension of the patterns of auto-
nomic imbalance and circadian disruption in RHTN is
one more parameter to guide clinicians toward a holistic
treatment of hypertension and diabetes.
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